ImmuCell Corporation
ICCC
$5.19
$0.122.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.49M | 23.84M | 23.22M | 21.28M | 17.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.49M | 23.84M | 23.22M | 21.28M | 17.47M |
| Cost of Revenue | 18.15M | 16.94M | 16.65M | 14.89M | 13.08M |
| Gross Profit | 8.35M | 6.89M | 6.58M | 6.39M | 4.40M |
| SG&A Expenses | 5.68M | 5.49M | 5.45M | 5.11M | 5.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.73M | 26.58M | 26.57M | 24.55M | 22.69M |
| Operating Income | -1.23M | -2.74M | -3.35M | -3.27M | -5.22M |
| Income Before Tax | -2.15M | -3.81M | -4.05M | -3.89M | -5.77M |
| Income Tax Expenses | 9.90K | 5.20K | 4.10K | 4.30K | 4.50K |
| Earnings from Continuing Operations | -2.16 | -3.81 | -4.05 | -3.90 | -5.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.16M | -3.81M | -4.05M | -3.90M | -5.77M |
| EBIT | -1.23M | -2.74M | -3.35M | -3.27M | -5.22M |
| EBITDA | 1.45M | -49.80K | -633.60K | -537.70K | -2.50M |
| EPS Basic | -0.28 | -0.49 | -0.52 | -0.50 | -0.75 |
| Normalized Basic EPS | -0.15 | -0.26 | -0.31 | -0.30 | -0.45 |
| EPS Diluted | -0.29 | -0.50 | -0.53 | -0.51 | -0.75 |
| Normalized Diluted EPS | -0.15 | -0.26 | -0.31 | -0.30 | -0.45 |
| Average Basic Shares Outstanding | 32.66M | 31.48M | 31.06M | 30.99M | 30.99M |
| Average Diluted Shares Outstanding | 32.66M | 31.48M | 31.06M | 30.99M | 30.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |